TOPIC : Creation of a pan-European Paediatric Clinical Trials Network
|Publication date:||21 December 2016|
|Types of action:||IMI2-RIA Research and Innovation action|
|DeadlineModel: Opening date:||two-stage 04 January 2017||Deadline: 2nd stage Deadline:||
28 March 2017 17:00:00
19 October 2017 17:00:00
|Time Zone : (Brussels time)|
01 August 2017 15:51
An overview of the evaluation results (flash call info – IMI2 Call 10 – stage one) is now available under the call ‘Additional documents’ tab.
Topic DescriptionSpecific Challenge:
Publications have previously shown that only 30% of marketed drugs in Europe and worldwide include a paediatric authorisation and less than 50% of authorised medicines commonly used in children had been properly tested in this population. This rate drops 10% in the vulnerable patient population in neonatal intensive care units. Even if the situation may improve with the different paediatric legislation in place, there is still a major societal challenge to be addressed.
There are many scientific and operational challenges faced by both pharma companies and academia when running paediatric clinical trials. Given the paucity of patients available for study in many paediatric indications and the need for multiple capable sites to satisfy enrolment in trials, the clinical trial infrastructure across the EU is not sufficiently organised, and lacks adequate funds and scale to consistently and efficiently deliver both industry-sponsored and academic non-industry sponsored clinical trials leading to new drug approval, complete labelling of existing drugs, valid comparisons between existing marketed therapies, or observational studies informing the natural history of disease indications.
A broad multidisciplinary public-private consortium is required to meet the challenges and be transformative for collectively addressing children’s needs for better medicines.Scope:
The overall vision of this topic is to create a large collaborative paediatric network that facilitates the development and availability of new drugs and other therapies, and the expansion of knowledge about drugs currently in practice for the entire paediatric population.
To achieve this vision the objectives are to:
- Create the network with a lean central coordinating organisation, arranged around “national hub coordinating centres” cooperating with multiple sites within each member state
- Set up scientific advice and trial readiness groups
- Test the viability of the network by conducting clinical studies
- Develop and implement a sustainable business model for the network
- Prepare the network to European Network for Paediatric Research at the European Medicines Agency (Enpr-EMA) membership
This project will have an impact on a number of areas including
- Better access for paediatric patients to new experimental therapies
- Increased efficiency of executing trials (reduced timelines & cost)
- Enhanced role of clinicians and patient/parent advocacy groups in planning and designing studies
- Opportunity for European clinical research personnel, clinical research sites, and clinical research organisations to collaborate across national borders making Europe a more competitive place for the conduct of paediatric clinical trials
Topic conditions and documents
Please read carefully all provisions below before the preparation of your application.
You can access the description of the different topics in the Call 10 topics text.
The budget breakdown for this Call is given at the end of the Call topics text, in the Conditions for this Call for proposals section, as well as the following information :
- List of countries and applicable rules for funding
- Eligibility and admissibility conditions
- Evaluation criteria and procedure, scoring and treshold: described in the IMI2 Manual for evaluation, submission and grant award.
- Indicative timetable for evaluation and grant agreement
- Provisions, proposal templates and evaluation forms for the type of actions under the Call topics:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Proposal templates are available after entering the submission tool
Standard evaluation form
IMI2 Model Grant Agreement
Template for essential clinical trials information
- Flash Call Info Report en
No submission system is open for this topic.
Contact the IMI Programme Office : E-mail: Infodesk@imi.europa.eu | Tel : +32 2 221 81 81
Contact you SRG member for assistance: IMI States Representative Group (SRG)
IMI Partner Search Tool helps you find a partner organisation for your proposal.
IT Helpdesk- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
National Contact Points (NCP) - contact your NCP for further assistance.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
Ethics – for compliance with ethical issues, check the information available on the Participant Portal, on the Science and Society Portal and in the The European Charter for Researchers and the Code of Conduct for their recruitment
IP – European IPR Helpdesk assists you on intellectual property issues
CEN and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at email@example.com.